The diagnosis of Bartter's syndrome was made in a 9-month-old boy investigated for poor weight and height gain. Initial treatment with oral potassium supplements and later spironolactone had little or no effect on his growth, although plasma potassium rose to normal after spironolactone. At 33 months indomethacin therapy was started with dramatic results. His symptoms went and his height and weight accelerated into the normal range. In view of the toxicity of indomethacin it was replaced after 12 months by another prostaglandin synthetase inhibitor, ketoprofen, with a satisfactory result. During the change-over period from indomethacin to ketoprofen the expected deterioration in clinical well-being was observed, accompanied by a rise in urinary prostaglandins and plasma renin activity. Prostaglandin synthetase inhibitors provide the best available treatment for Bartter's syndrome.
In 1962 Bartter and colleagues described a syndrome of hypokalaemia, alkalosis, raised plasma renin activity, and hypertrophy of the juxtaglomerular apparatus but without hypertension. In children there is associated growth failure (Bryan et al., 1966) . Several groups of investigations had suggested that there was an obligate loss of sodium in the urine of patients with this disorder (Cannon et al., 1968; Lee, 1969) . It had also been proposed that there could be an inappropriate production of renin and on this basis beta-adrenergic blocking agents, such as propanolol, had been tried (Modlinger et al., 1973) .
In 1975 Belgian workers (Verberckmoes et al., 1976) observed hyperplasia of the renomedullary interstitial cells in Bartter's syndrome. In view of the suggested association of these cells with prostaglandin production (Muirhead et al., 1972) , they administered a known inhibitor of prostaglandin synthetase (indomethacin) to an adult patient with this disorder. The initial results were excellent and this finding has been confirmed by others in the United States (Fichman et al., 1976; Gill et al., 1976) .
We report here the diagnosis of Bartter's syndrome in an infant and its successful treatment with indomethacin. The long-term use ofthis drug presents certain difficulties. There is a substantial incidence of gastric erosions and also serious side effects within the central nervous system including headache and hallucinations. We therefore changed his therapy to ketoprofen, a known prostaglandin synthetase inhibitor, with fewer reported side effects (Fossgreen et al., 1975) . During the change-over period detailed study was made of clinical and biochemical changes.
Methods
Plasma renin activity was determined by a modification of the method of Ryan et al. (1968) When first seen at age 9 months he weighed 6 75 kg (1 kg below 3rd centile) and was 70-5 cm long (50th centile). He was pale and very thin; the ears were slightly prominent; his eyes were blue but there was a small brown quadrant in the right iris; the wasting was of both subcutaneous tissue and muscles, and the latter were markedly hypotonic. The cardiovascular system was normal; blood pressure 100/55 mmHg with a 7 cm cuff. Small hard faecal masses were palpable in the abdomen. General developmental progress was thought to be within normal limits for age. Urine examination was negative for glucose, total reducing substances, albumin, and blood. pH was 7 0.
Investigations. Plasma electrolytes at 9 months: K 2-4, Na 131, bicarbonate 30, urea 5-8 mmol/l (34-9 mg/100 ml). Urine electrolytes: K 87, Na 85, and Cl 81 mmol/l. Blood pH was 7-59, Pco2 4-6 kPa (33 mmHg), and base excess 10-1 mmol/l. Two determinations of plasma renin activity showed levels of 23 100 and 27 800 pg/ml per hour (Dr M. Dillon: normal 50-500 pg/ml per hour). Plasma aldosterone was 36 ng/100 ml (0 999 nmol/l) (normal) and urinary aldosterone was 15 jg/24 hours (high normal). Hb was 11-5 g/dl (79%), and white blood count 11 5 x 109/l. Differential white blood count and blood film were normal.
Other investigations were calcium 2-5 mmol/l (10 mg/100 ml), phosphorus 1 5 mmol/l (4 64 mg/100 ml), serum cholesterol 4-8 mmol/l (185 mg/100 ml), triglyceride 2-0 mmol/l (177 mg/100 ml). Alkaline phosphatase 35-5 King-Armstrong units/ 100 ml. Magnesium 0-8 mmol/l (1-95 mg/100 ml).
Urinary oxosteroids (ketosteroids) 3x0 [umol (0-86 mg) per 24 hours; 17-oxogenic steroids (hydroxycorticosteroids) 5 9 ,umol (1-7 mg) per 24 hours. Urine culture and microscopy were negative. Whole body potassium (age 14 months) showed a total K content of 412 mmol, equivalent to 51 2 mmol/kg body weight (normal). X-rays of the chest and abdomen were normal and wrist x-ray showed a bone age of 9 months (Greulich and Pyle method). Intravenous pyelogram: left kidney 9 0 cm and right kidney 8 8 cm (1 SD above the mean for a height of 71 cm).
The kidneys, ureters, and bladder were normal. Barium swallow was normal. Electrocardiogram showed changes compatible with mild hypokalaemia. Sweat test: Na 22 mmol/l, Cl 9 mmol/l.
Treatment and progress. The diagnosis was suggested on the first electrolyte results and confirmed by the markedly raised renin levels in the presence of a normal blood pressure. Treatment was started at 11 months by increasing the dietary intake ofpotassium. The addition of K supplements to a total of approximately 80 mmol/day caused an encouraging but transient weight gain but had no effect on plasma K levels. Spironolactone (18 75 mg/day) was added at 18 months and although plasma K returned to low normal levels, there was no effect on his poor growth and weight gain. Magnesium supplements were added at the age of 2 years 2 months, without obvious clinical or biochemical benefit.
At 2 years 4 months Na intake was increased by the addition of 3 0 g NaCl per day. Although this was followed by an increase in the thirst which had been noted as a clinical feature during the second year, there was a definite increase in activity and well-being but no improvement in his growth, either in rate of weight or height gain. The added sodium was therefore discontinued.
At 2 years 9 months indomethacin therapy was added to the increased dietary K (80 mmol/day) and the spironolactone (18-75 mg/day). The effect on symptoms and growth was dramatic. Within 2 days thirst and polyuria stopped and the constipation improved. There was a marked increase in appetite and general well-being. Improved growth was evident on the growth chart and coincided with the start of indomethacin (Fig. 1) , which was started in small doses of 2-5 mg tds and gradually increased to 7.5 mg, 5 mg, 7-5 mg daily over a 4-week period.
Plasma K failed to return to normal levels but Na returned to normal for the first time after life-long hyponatraemia.
Metabolic study. At age 3 years 9 months, after 12 months of indomethacin, therapy was changed to ketoprofen. A metabolic study lasting 15 days was carried out, comprising 8 days on indomethacin 20 mg daily, 4 days off treatment, and 3 days on ketoprofen 30 mg daily (Fig. 2) In the 4-day period after indomethacin was stopped (days 9-12 inclusive), he was well but thirst increased from day 10 onwards. This was partially relieved after starting ketoprofen on day 13, but not completely controlled for some 6 weeks by which time ketoprofen dosage had been gradually increased to 60 mg daily.
The data derived from this metabolic study are given in the Table. Urine volume, Na intake and output, and body weight are shown in Fig. 2 Although it has been considered from animal studies that ketoprofen is equipotent with indomethacin, the initial response to 2-3 mg/kg per day of ketoprofen was somewhat unsatisfactory and the dose was therefore raised to 4-6 mg/kg in divided doses. There have been no serious side effects from either drug. At the moment the response to treatment has to be judged on height and weight gain, the elimination of thirst and polyuria, and the plasma electrolytes. In future it may be possible to monitor therapy by regular determination of urinary prosta- glandins and plasma renin activity but at the moment these techniques depend on difficult radioimmunoassays which are not generally available.
The nature of the prostaglandin abnormality in Bartter's syndrome remains controversial. Gill et al. (1976) measured urinary prostaglandin E, and F20 in several patients with the disorder and suggested that there was an increase in the urinary excretion of prostaglandin E2 but that changes in F2a were less remarkable. In their hands, treatment with indomethacin (100-200 mg/day) decreased urinary prostaglandin E2-like material by 69 %. Plasma renin activity and urinary aldosterone fell substantially on the anti-inflammatory drug. Our urinary prostaglandin results suggest that when therapy with indomethacin was stopped, prostaglandin E2 increased fivefold (as did F2cx). However, the peak of prostaglandin E2 excretion corresponded more closely with the duration of relapse, whereas the excretion of F,m had begun to fall before ketoprofen therapy was started. Another major prostaglandin produced by the renal medulla is prostaglandin A2 and this has been shown to be increased in the urine of patients with Bartter's syndrome by Fichman et al. (1976) . Muirhead et al. (1972) have also shown that tissue cultures of renomedullary interstitial cells can convert arachidonic acid to the three prostaglandins, A2, E2, and F2o.
It has been suggested that the balance between vasoconstriction and vasodilatation in the kidney, and the resulting changes in sodium handling is determined not by the absolute amount of prostaglandin synthetase produced by the renal tissue but by the ratio between prostaglandin E1 and E.. Thus, if prostaglandin E2 were vasodilator and natriuretic then E1 would be vasoconstrictor and sodium retaining (Armstrong et al., 1976) . It is theoretically possible that the ratio of prostaglandin E1 to E2 could be manipulated artificially, increasing E2 by dietary administration of arachiodonic acid or, alternatively, E1 by the administration of dihomogammalinolenic acid (Willis et al., 1974) .
Until recently the diagnosis of this rare disorder was a matter of academic interest as there was no effective treatment. The patients often remained small, had serious symptoms referable to their low plasma potassium, and some died as a result of chronic renal failure (Lancet, 1976) . The advent of specific therapy directed towards a long-term amelioration of the clinical syndrome makes the early diagnosis and treatment of this disorder imperative. There is now the expectation that many of these children will survive into adult life and avoid the serious consequences of their metabolic disturbance, provided that they are treated with prostaglandin synthetase inhibitors. 
